Thursday 6-12-2014 Mannkind Corp (MNKD) $MNKD open
Post# of 128
Overall Average: 80% Buy
Recent stock forum discussions about MNKD http://investorshangout.com/search?q=MNKD&...mp;yt0=Go!
MannKind Falls 5.49% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jun 12, 4:38PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $9.70 to a high of $10.45. Yesterday, the shares fell 5.5%, which took the trading range below the 3-day low of $10.10 on volume of 14.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
MannKind Corporation's Date With Destiny
Brian Orelli, The Motley Fool - Motley Fool - Wed Jun 11, 7:01PM CDT
Editor's Note: MannKind's PDUFA date is July 15th -- it was accidentally noted as June 15th. The Fool regrets the error. MannKind 's PDUFA date is July 15, so we'll be watching carefully to see whether the Food and Drug Administration will... (full story)
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 08, 8:00AM CDT
What a week for the major indexes! The S&P 500 and Dow both ended at record highs. The success of the broader markets paled in comparison to a handful of health-care stocks, though. One of this week's soaring stocks received good news from... (full story)
May's 3 Best Biotech Stocks
Todd Campbell, The Motley Fool - Motley Fool - Fri Jun 06, 5:00PM CDT
Last month, shares in most biotech companies moved higher as investors began returning to the basket following a significant drop in the first quarter. Among those leading the move higher were MannKind , Intrexon Corp , and Ophthotech Corp . ... (full story)
Uptrend Call Working As MannKind Stock Rises 33.1% (MNKD)
Comtex SmarTrend(R) - Fri Jun 06, 9:40AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 2 months, MannKind has returned 33.08% as of today's recent price of $9.92. (full story)
Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition
at The Street - Fri Jun 06, 9:32AM CDT
I've been getting so much hate mail and nasty tweets lately, I thought it would be fun to throw them all into a single column for funny Friday read. There's probably something deeper to be said about market psychology and what an uptick in hate mail... (full story)
Critical Alerts For Netflix, MannKind, Dish Network, Illumina, and Anheuser-Busch InBev Technology Released By InvestorsObserver
PR Newswire - Fri Jun 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for NFLX, MNKD, DISH, ILMN, and BUD. (full story)
MannKind Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 06, 7:00AM CDT
Shares of MannKind (MNKD) hit a 52-week high of $11.11 during the trading session on Jun 5 (full story)
Most active Nasdaq-traded stocks
AP - Thu Jun 05, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading: (full story)
Nasdaq stocks posting largest percentage increases
AP - Thu Jun 05, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: (full story)
MannKind (MNKD) Hits 52-Week High As Afrezza FDA Approval Approaches
at The Street - Thu Jun 05, 9:37AM CDT
MannKind (MNKD) surged to a 52-week high of $11.11 on Thursday on high volume as the impending July 15 date for FDA approval of the company's inhaled insulin drug Afrezza approaches. (full story)
MannKind Corp. (MNKD) Soars: Stock Adds 10.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 8:21AM CDT
MannKind Corp. (MNKD) was a big mover last session, as the company saw its shares rise by almost 11% on the day. (full story)
The Expected Rise and Inevitable Fall of MannKind
at The Street - Thu Jun 05, 8:01AM CDT
Using Arena Pharmaceuticals (a very similar, retail-driven cult stock) as a precedent, MannKind should go even higher as we get closer to July 15, but if/when Afrezza is approved, the sell off begins. (full story)
Why MannKind is the Ultimate Battleground Stock
George Budwell, The Motley Fool - Motley Fool - Wed Jun 04, 1:42PM CDT
Short-sellers usually have good reason when they jump into a stock with both feet. That said, shorts aren't always correct in their assessment of a company's prospects, potentially setting up a highly profitable phenomenon known as a "short squeeze"... (full story)
MannKind (MNKD) Surges to 52-Week High as Afrezza Approval Approaches
at The Street - Wed Jun 04, 10:58AM CDT
MannKind (MNKD) surged to a 52-week high on Wednesday on high volume as the impending July 15 date for FDA approval of the company's inhaled insulin drug Afrezza approaches. (full story)
After Yesterday's Rally of 5.32% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Jun 03, 4:37PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $9.01 to a high of $9.56. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high of $9.46 on volume of 13.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
4 Stocks That Soared in May
Rick Munarriz, The Motley Fool - Motley Fool - Mon Jun 02, 3:16PM CDT
There were some pretty surprising winners last month. Bucking the "sell in May" mantra, these unlikely companies roared to life. Investors didn't mind, of course. Let's go over a couple of the stocks that put the pedal to the metal. MannKind --... (full story)
3 Huge Stocks Everyone Is Talking About
at The Street - Mon Jun 02, 8:08AM CDT
Here's how to trade some of the most active stocks on the market today. (full story)